NeuBase's newest advisors are former National Cancer Institute director and Harvard geneticist
Pittsburgh ’s newest publicly traded company has made two high-powered additions to its scientific advisory board.
NeuBase Therapeutics Inc. said in a release that Dr. Samuel Broder and George Church bring expertise in genetics, genomics and oncology and will work closely with its management team.
NeuBase (Nasdaq:NBSE) is a biotechnology company developing next-generation antisense therapies to address genetic diseases.
Broder was director of the National Cancer Institute from 1989 through 1995…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Patty Tascarella Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Genetics | Harvard | Health Management | Pharmaceuticals